Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Mexico - Delayed Quote MXN

Bionano Genomics, Inc. (BNGO.MX)

Compare
96.89
+4.97
+(5.41%)
At close: April 11 at 1:49:58 PM CST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in MXN.
NameTitlePayExercisedYear Born
Dr. Robert Erik Holmlin M.B.A., Ph.D. President, CEO & Director and CFO 12.31M -- 1968
Mr. Mark Oldakowski Chief Operating Officer 9.51M -- 1974
Dr. Alka Chaubey FACMG, Ph.D. Chief Medical Officer 9.1M -- 1973
Mr. Mark Adamchak CPA VP of Accounting & Controller -- -- --
Mr. Jonathan Dixon J.D. General Counsel & Secretary -- -- 1975
Mr. Stanislas Marin M.B.A., M.S. Vice President of Global Sales -- -- --
Ms. Donna Polizio Global Head of Market Access -- -- --
Mr. Cory Kreeck Global Head of People Operations -- -- --

Bionano Genomics, Inc.

9540 Towne Centre Drive
Suite 100
San Diego, CA 92121
United States
858 888 7600 https://www.bionano.com
Sector: 
Healthcare
Full Time Employees: 
98

Description

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The company offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. It also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic data from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, the company offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Corporate Governance

Bionano Genomics, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 9. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 6, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC

Bionano Genomics, Inc. Earnings Date

Recent Events

Related Tickers